(lp0
S'Momenta Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 17 Equities.com - 18 hours ago Momenta Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock lost 0.72% to close at $13.75.EPS Projection Of Momenta Pharmaceuticals, Inc.  At $0.28 - RealistInvestor.comNext Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc.  - Fiscal Standard'
p1
aS"Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat Motley Fool - Feb 22, 2017 Momenta Pharmaceuticals  reported fourth-quarter earnings on Tuesday, but analysts weren't discussing the numbers."
p2
aS'Why Momenta Pharmaceuticals, Inc. Jumped Higher Today Motley Fool - Oct 11, 2016 Before then, it seems likely Momenta will try and partner M923 . Last month, Momenta announced that it will regain rights to the drug from Shire.Momenta Pharmaceuticals  Stock Surges, Barclays Upgrades - TheStreet.com'
p3
aS'Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today Motley Fool - Jan 31, 2017 Shares of Momenta Pharmaceuticals  are up over 20% at 12:28 p.m. EST after the company announced that the U.S.Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher - 24/7 Wall St.'
p4
aS"Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa ... GlobeNewswire  - Feb 17, 2017 CAMBRIDGE, Mass., Feb. 17, 2017  -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Sandoz's contracted&nbsp;...Momenta Pharma shares halted as drug application hits speed bump - MarketWatchMomenta halted after noting compliance issue in drug application - Seeking Alpha"
p5
aS'Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and ... GlobeNewswire  - Nov 2, 2016 CAMBRIDGE, Mass., Nov. 02, 2016  -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M.Mylan, Momenta move ahead in trial for rheumatoid arthritis drug - Pittsburgh Business Times'
p6
aS"Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead? Motley Fool - Aug 9, 2016 While the report included sales of Momenta's and partner Novartis AG's  Glatopa, the generic version of Teva Pharmaceutical Industries'  once-daily Copaxone, investors should focus on the potential approval of the generic&nbsp;..."
p7
aS"Tuesday's Market Insights: DryShips Inc. , Momenta Pharmaceuticals, Inc ... Smarter Analyst - Feb 21, 2017 Momenta Pharmaceuticals, Inc.  shares are trading down 14% after the complex pharmaceutical company announced that a warning letter had been delivered from the FDA to Pfizer, Sandoz's contracted manufacturer for Glatopa, a drug&nbsp;..."
p8
aS'A Somewhat Murky Outlook For Momenta Pharmaceuticals Seeking Alpha - Dec 28, 2016 Although I have made some good gains from Momenta Pharmaceuticals over the past few months, it is one of the murkiest companies I follow in the biotech space.'
p9
aS'Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors GlobeNewswire  - Sep 23, 2016 CAMBRIDGE, Mass., Sept. 23, 2016  -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N.'
p10
a.